J. Palmer

发表

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.

W. Castle, R. Fuller, J. Hall, 1993, BMJ.

Muscling in on salbutamol

P. Myles, J. Palmer, G. Shepherd, 1992, The Lancet.

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.

J. Palmer, B. Lundback, D. Rawlinson, 1993, Thorax.

VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways.

P. Barnes, J. Palmer, F. Cuss, 1986, Journal of applied physiology.

Neuropeptides and airway smooth muscle function.

P. Barnes, J. Palmer, 1987, The American review of respiratory disease.

The actions of GR32191B, a thromboxane receptor antagonist, on the effects of inhaled PAF on human airways

D. Hendrick, M. Duddridge, E. Walters, 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

The effect of airway epithelium on smooth muscle contractility in bovine trachea

P. Barnes, J. Palmer, F. Cuss, 1985, British journal of pharmacology.

A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion.

N. Choudry, M. Adachi, K. O'Shaughnessy, 1992, The Journal of allergy and clinical immunology.

The effect of GR32191 (a thromboxane receptor antagonist) on airway responsiveness in asthma.

D. Hendrick, E. Walters, J. Palmer, 1992, Pulmonary pharmacology.

Corticosteroid pharmacokinetics in asthma

J. Palmer, S. Lane, I. F. Skidmore, 1990, The Lancet.

Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?

R. Fuller, J. Palmer, M. Devoy, 1995, Chest.

Effect of infused vasoactive intestinal peptide on airway function in normal subjects.

P. Barnes, J. Warren, J. Palmer, 1986, Thorax.

Phosphatidylinositol response to cholinergic agonists in airway smooth muscle: relationship to contraction and muscarinic receptor occupancy.

P. Barnes, J. Palmer, F. Cuss, 1986, The Journal of pharmacology and experimental therapeutics.

The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease.

A. Gulsvik, J. Palmer, L. Fjellbirkeland, 1994, Respiratory medicine.

Metabolic effects of salbutamol: comparison of aerosol and intravenous administration.

J. Palmer, K. Palmer, J. Gaddie, 1977, British medical journal.

Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma

M. Charter, B. Lipworth, J. Palmer, 1989, European Journal of Clinical Pharmacology.

Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma

B. Lipworth, J. Palmer, D. Dhillon, 2004, European Journal of Clinical Pharmacology.

Asthma Mortality and β-Agonists-To the Editor

R. Fuller, J. Palmer, M. Devoy, 1995 .

β2-agonists

M. Sears, D. Taylor, J. Palmer, 1991, The Lancet.

A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.

C. McArdle, D. Cunningham, S. Kaye, 1983, European Journal of Cancer and Clinical Oncology.

Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma.

S. Holgate, J. Palmer, J. Finnerty, 1991, Thorax.

A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.

J. Palmer, M. Britton, J. Earnshaw, 1992, The European respiratory journal.

Bronchodilator treatment in asthama: Authors' reply

W. Castle, R. Fuller, J. Hall, 1993 .

Glyceryl trinitrate reversal of post-sumatriptan coronary artery narrowing

J. Palmer, R. Feldman, GBJohn Mancini, 1995, The Lancet.

BETA 2-AGONISTS

M. Sears, D. Taylor, J. Palmer, 1991 .

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms).

J. Palmer, K. Viskum, G. Shepherd, 1992, Respiratory medicine.

Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease.

R. Dahl, J. Palmer, J. Earnshaw, 1991, The European respiratory journal.

Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated.

J. Palmer, A. Ciociola, D. Sykes, 1999 .

Protection against allergen-induced asthma by salmeterol

S. Holgate, J. Palmer, O. P. Twentyman, 1990, The Lancet.

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease — a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 μg) with salmeterol (50 μg)

J. Palmer, K. Viskum, G. Shepherd, 1992 .

Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated

J. Palmer, A. Ciociola, D. Sykes, 1999, American Journal of Gastroenterology.

Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma.

D. Newnham, J. Palmer, D. Dhillon, 1993, Respiratory Medicine.

Exacerbations of asthma in patients on salmeterol

J. Palmer, M. M. Jenkins, C. J. Hilton, 1991, The Lancet.

Clinical Efficacy, Tolerance and Pharmacokinetics of Temocillin in Patients with Respiratory Tract Infections

J. Palmer, J. Legge, T. Reid, 2012, Drugs.

Rapid estimation of plasma theophylline concentrations.

P. Barnes, J. Palmer, F. Cuss, 1985, British medical journal.

Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.

J. Palmer, R. Clark, A. Hutcheon, 1983, Cancer treatment reports.